COMBINATION OF mRNA EXPRESSION LEVELS OF DLX1 AND HOXC6 IN URINE AS MOLECULAR MARKERS IN PROSTATE CANCER

Abstract

The present invention relates to methods for diagnosing prostate cancer and especially diagnosing LG, HG, PrCa Met and CRPC. Specifically, the present invention relates to methods for in vitro diagnosing prostate cancer in a human individual comprising: 1) determining the expression of one or more genes chosen from the group consisting of ACSM1, ALDH3B2, CGREF1, COMP, C19orf48, DLX1, GLYATL1, MS4A8B, NKAIN1, PPFIA2, PTPRT, TDRD1 and/or UGT2B15; and 2) establishing up regulation of expression of said one or more genes as compared to expression of the respective one or more genes in a sample from an individual without prostate cancer thereby providing said diagnosis of prostate cancer.

1 .- 27 . (canceled) 
     
     
         28 . A method comprising:
 (a) detecting DLX1 mRNA in a urine sample comprising prostate cells from a subject by converting mRNA in the urine sample to cDNA and detecting DLX1 cDNA;   (b) detecting HOXC6 mRNA in the urine sample comprising prostate cells from the subject by converting mRNA in the urine sample to cDNA and detecting HOXC6 cDNA; and   (c) detecting a high grade prostate cancer in the subject.   
     
     
         29 . The method of  claim 28 , wherein the cDNA is detected in step (a) and step (b) by amplifying the cDNA by performing a polymerase chain reaction. 
     
     
         30 . The method of  claim 28 , wherein the urine sample is a first voided urine sample collected after a digital rectal examination. 
     
     
         31 . A method comprising:
 (a) detecting DLX1 mRNA in a urine sample comprising prostate cells from a subject;   (b) detecting HOXC6 mRNA in the urine sample comprising prostate cells from the subject; and   (c) detecting a high grade prostate cancer in the subject.   
     
     
         32 . The method of  claim 31 , wherein the urine sample is a first voided urine sample collected after a digital rectal examination. 
     
     
         33 . A method comprising:
 (a) isolating RNA from a urine sample comprising prostate cells from a subject;   (b) converting the isolated RNA to cDNA;   (c) contacting the cDNA with an array;   (d) amplifying the cDNA; and
 (i) detecting DLX1 cDNA; and 
 (ii) detecting HOXC6 cDNA; and 
   (e) detecting a high grade prostate cancer in the subject.   
     
     
         34 . The method of  claim 33 , wherein the urine sample is a first voided urine sample collected after a digital rectal examination. 
     
     
         35 . The method of  claim 28  further comprising:
 (c) detecting TDRD1 mRNA in the urine sample by converting mRNA in the urine sample to cDNA and detecting TDRD1 cDNA. 
 
     
     
         36 . A method of  claim 31  further comprising:
 (c) detecting TDRD1 mRNA in the urine sample. 
 
     
     
         37 . A method of  claim 33  further comprising:
 (iii) detecting TDRD1 cDNA. 
 
     
     
         38 . The method of  claim 28 , wherein detecting a high grade prostate cancer comprises determining a Gleason score for a prostate biopsy from the subject. 
     
     
         39 . The method of  claim 31 , wherein detecting a high grade prostate cancer comprises determining a Gleason score for a prostate biopsy from the subject. 
     
     
         40 . The method of  claim 33 , wherein detecting a high grade prostate cancer comprises determining a Gleason score for a prostate biopsy from the subject.